Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 10, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of specific share transactions and does not contain financial performance data.
Material Changes
The filing details specific transactions involving the SmithKline Beecham Employee Benefit Trust ("the Trust") on October 4, 2005:
- Share Sale: 1,009 Ordinary shares were sold on behalf of a participant in the GlaxoSmithKline Annual Investment Plan at a price of GBP 14.5836 per share.
- Share Transfer: 3,404 Ordinary shares were transferred from the Trust to a participant in the GlaxoSmithKline Annual Investment Plan.
Director Mr. J. Heslop is noted as having an interest in the shares held in the fund, consistent with other non-US employees or former employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the aforementioned share transactions in accordance with Disclosure Rule 3.1.4R(1)(b).
Investor Verification Points
- Verify the total number of shares held by the SmithKline Beecham Employee Benefit Trust following the reported sale and transfer.
- Confirm the aggregate value of the transaction based on the reported price of GBP 14.5836.
- Review the full composition of the Trust to understand the scope of Director Mr. J. Heslop's indirect interest.